Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) have been given a consensus rating of “Moderate Buy” by the sixteen research firms that are currently covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $25.56.
A number of research analysts recently commented on the company. Stifel Nicolaus decreased their price objective on ACADIA Pharmaceuticals from $26.00 to $21.00 and set a “hold” rating on the stock in a report on Thursday, May 9th. Mizuho decreased their price objective on ACADIA Pharmaceuticals from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Thursday, May 9th. StockNews.com cut ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 3rd. Bank of America decreased their price objective on ACADIA Pharmaceuticals from $26.00 to $22.00 and set a “neutral” rating on the stock in a report on Friday, May 10th. Finally, Cantor Fitzgerald decreased their price objective on ACADIA Pharmaceuticals from $37.00 to $28.00 and set an “overweight” rating on the stock in a report on Wednesday, August 7th.
Read Our Latest Analysis on ACAD
Insider Transactions at ACADIA Pharmaceuticals
Hedge Funds Weigh In On ACADIA Pharmaceuticals
Several large investors have recently bought and sold shares of ACAD. Fisher Asset Management LLC purchased a new position in ACADIA Pharmaceuticals in the fourth quarter valued at $4,479,000. Natixis Advisors L.P. increased its holdings in ACADIA Pharmaceuticals by 17.6% in the fourth quarter. Natixis Advisors L.P. now owns 40,875 shares of the biopharmaceutical company’s stock valued at $1,279,000 after buying an additional 6,112 shares during the last quarter. Los Angeles Capital Management LLC increased its holdings in ACADIA Pharmaceuticals by 43.9% in the fourth quarter. Los Angeles Capital Management LLC now owns 65,179 shares of the biopharmaceutical company’s stock valued at $2,041,000 after buying an additional 19,871 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in ACADIA Pharmaceuticals by 5.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,127,907 shares of the biopharmaceutical company’s stock valued at $35,315,000 after buying an additional 54,814 shares during the last quarter. Finally, E Fund Management Co. Ltd. boosted its stake in ACADIA Pharmaceuticals by 32.4% in the fourth quarter. E Fund Management Co. Ltd. now owns 22,893 shares of the biopharmaceutical company’s stock valued at $717,000 after acquiring an additional 5,605 shares in the last quarter. Hedge funds and other institutional investors own 96.71% of the company’s stock.
ACADIA Pharmaceuticals Price Performance
Shares of ACADIA Pharmaceuticals stock opened at $16.32 on Friday. The stock has a market cap of $2.70 billion, a P/E ratio of -1,632.00 and a beta of 0.38. The stock’s 50 day simple moving average is $16.82 and its 200-day simple moving average is $17.85. ACADIA Pharmaceuticals has a 1-year low of $14.55 and a 1-year high of $32.59.
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.02. ACADIA Pharmaceuticals had a negative return on equity of 0.41% and a negative net margin of 0.21%. The business had revenue of $241.96 million for the quarter, compared to analysts’ expectations of $235.95 million. During the same period in the previous year, the firm posted $0.01 EPS. The business’s revenue for the quarter was up 46.4% compared to the same quarter last year. As a group, research analysts expect that ACADIA Pharmaceuticals will post 0.58 EPS for the current fiscal year.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.
See Also
- Five stocks we like better than ACADIA Pharmaceuticals
- Earnings Per Share Calculator: How to Calculate EPS
- Does A&F’s Q2 Earnings Win Point to a Strong Holiday Season?
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Best Buy Stock Flashes Bullish Signal, Challenges Remain
- Investing in Commodities: What Are They? How to Invest in Them
- Affirm Shows Buy-Now-Pay-Later Is Here to Stay in Latest Results
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.